- 医療薬学 (ISSN:1346342X)
- vol.45, no.11, pp.610-615, 2019-11-10 (Released:2020-11-11)
“LANTUS® XR Inj. Solostar® (450 units / 1.5 mL)” is a preparation that tripled the insulin concentration of existing LANTUS® Inj. Solostar®. As the volume per insulin unit is reduced to one third, the recommended blank beating units before dosing have been increased to 3 units. However, some patients perform 2-unit blank beating as they use the existing injector. A retrospective investigation identified erroneous operation of blank beating in 9.5% of outpatients who had been prescribed LANTUS® XR Inj. Solostar® at Nagoya Ekisaikai Hospital from April to May 2017. In this study, we investigated if 2-unit blank beating with LANTUS® XR Inj. Solostar® is suitable to confirm needle hole clogging and injection of content by naked-eye observation and the amount emitted. Injection of content was confirmed at the second and subsequent 2-unit beatings by naked-eye observation. On the other hand, the emission weighing test with a new needle and syringe barrel revealed that the amount discharged was increased with 2-unit beating and reached the theoretical value at the fourth beating. Based on these results, we concluded that 3-unit blank beating is preferable for LANTUS® XR Inj. Solostar®; however, three successive 2-unit blank beatings are helpful to confirm correct installation of the needle and normal movement of the injector.